What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

1 day ago 5

Jonathan Ponciano, The Motley Fool

Sat, November 29, 2025 astatine 12:48 PM CST 5 min read

San Francisco-based 5AM Venture Management sold 150,000 CNTA shares successful the 3rd quarter.
Despite the sale, the stock's crisp rally past 4th led the fund's nett presumption worth successful CNTA to summation by $5.6 million.
5AM inactive holds a sizable involvement successful CNTA, with 680,945 shares valued astatine $16.5 million, putting it arsenic the fund's fifth-largest position.
These 10 stocks could mint the adjacent question of millionaires ›

San Francisco-based 5AM Venture Management reduced its involvement successful Centessa Pharmaceuticals (NASDAQ:CNTA) by 150,000 shares successful the 3rd quarter, according to a November 14 SEC filing.

According to a filing published with the Securities and Exchange Commission connected November 14, 5AM Venture Management disclosed a simplification successful its Centessa Pharmaceuticals position. The money reported holding 680,945 shares, down by 150,000 shares from the erstwhile quarter. Despite the sale, the wide presumption worth inactive accrued fixed the stock's crisp emergence past 4th of much than 80%. The revised involvement was valued astatine astir $16.5 cardinal arsenic of September 30, representing astir 6.1% of the fund’s astir $273 cardinal successful reportable assets.

Top 5 holdings aft the update:

NASDAQ:SKYE: $38 cardinal (13.9% of AUM)
NASDAQ:TRDA: $24.7 cardinal (9.0% of AUM)
NASDAQ:PHVS: $19.9 cardinal (7.3% of AUM)
NASDAQ:CAMP: $17.6 cardinal (6.4% of AUM)
NASDAQ:CNTA: $16.5 cardinal (6.0% of AUM)

As of Friday, Centessa shares were priced astatine $29.03, up a staggering 65% implicit the past twelvemonth and acold outperforming the S&P 500, which is up 14% successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent Friday)	$29.03
Market capitalization	$4.2 billion
Revenue (TTM)	$15. million
Net income (TTM)	($242.7 million)

Centessa Pharmaceuticals is simply a biotechnology institution headquartered successful the United Kingdom that is processing a pipeline of clinical-stage biopharmaceutical products, including Lixivaptan for autosomal ascendant polycystic kidney illness and SerpinPC for hemophilia, arsenic good arsenic early-stage assets targeting uncommon diseases and immunological conditions. Centessa targets patients with uncommon and superior diseases, arsenic evidenced by its objective programs successful conditions specified arsenic hemophilia, autosomal ascendant polycystic kidney disease, alpha-1-antitrypsin deficiency, pulmonary arterial hypertension, and definite autoimmune diseases. The institution serves a planetary basal of patients, healthcare providers, and probe institutions focused connected uncommon and underserved aesculapian conditions.

Trimming a presumption aft a large rally tin beryllium arsenic telling arsenic doubling down—especially erstwhile the underlying subject is inactive aboriginal but showing existent momentum. Centessa has go 1 of the sector’s standout performers, and the biotech-focused fund’s determination to reduce—not exit—its involvement signals continued condemnation adjacent arsenic the company’s valuation has surged connected objective progress.

Centessa’s orexin agonist level remains the cardinal driver. In its latest update, absorption reported Phase 2a information showing “statistically significant, clinically meaningful and dose-dependent” improvements crossed wakefulness measures for ORX750, with a favorable information illustration crossed cohorts. CEO Saurabh Saha called the information “significant progress” and highlighted plans to statesman a registrational programme successful the archetypal 4th of 2026. Financially, Centessa posted a third-quarter nett nonaccomplishment of $54.9 cardinal and ended the 4th with $349 cardinal successful cash, equivalents, and investments—enough to money operations into mid-2027. The institution besides strengthened its equilibrium expanse with an announced $250 cardinal nationalist offering astatine $21.50 per ADS.

For semipermanent investors, the takeaway is clear: The trimmed presumption apt reflects portfolio management, not diminishing confidence. The champion evidennce is that the money kept Centessa among its apical holdings, underscoring the imaginable of a pipeline that could reshape attraction for aggregate sleep-wake disorders.